A deep dive into the market segments reveals distinct trends that underscore the diversity of the Indian pharmaceutical market. The India Pharmaceuticals Industry Market is segmented by therapeutic category and drug type, each telling a unique story about where the greatest demand lies and where the most significant growth opportunities are emerging.

By Therapeutic Category: Cardiovascular Dominates, Anti-Diabetic and Respiratory Grow

The market segmentation by therapeutic category includes Anti-Infectives, Cardiovascular, Gastrointestinal, Oral Anti-Diabetic, Respiratory, Dermatological, Musculo-Skeletal System, Nervous System, and Others.

The cardiovascular segment dominated the market in 2022. This dominance reflects the high and rising burden of cardiovascular diseases (CVDs) in India, which are the leading cause of death in the country. Pharmaceuticals classified as cardiovascular medications primarily affect the heart or blood vessels and are used to treat heart and circulation-related ailments. Examples include antiarrhythmics, antihypertensives (for high blood pressure), antianginals (for chest pain), anticoagulants (blood thinners), and cholesterol-lowering medications (statins). The rising prevalence of risk factors such as obesity, sedentary lifestyles, unhealthy diets, tobacco use, and stress is driving the growing incidence of CVDs, and consequently, the demand for cardiovascular medications.

The oral anti-diabetic segment is another major category, driven by India's status as the diabetes capital of the world. According to the International Diabetes Federation, India is home to over 70 million people with diabetes, a number expected to rise significantly in the coming years. The increasing prevalence of type 2 diabetes, linked to lifestyle changes and an aging population, fuels demand for oral anti-diabetic drugs including metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and other agents.

The respiratory segment is projected to grow at a substantial rate over the forecast period. Respiratory ailments affect the lungs and respiratory tract, with common conditions including lung cancer, pulmonary fibrosis, pneumonia, asthma, and chronic obstructive pulmonary disease (COPD). Rising air pollution levels in major Indian cities, increasing tobacco and smoking prevalence, exposure to radon, asbestos, and other pollutants, and ongoing research and development in the field are driving growth in this segment. The introduction of new products, including combination inhalers and biologic therapies for severe asthma, is also contributing to market expansion.

The anti-infectives segment remains important, driven by the high burden of infectious diseases in India, including tuberculosis, respiratory infections, urinary tract infections, and drug-resistant bacterial infections. The gastrointestinal, dermatological, musculo-skeletal, and nervous system (including CNS disorders and psychiatric conditions) segments also contribute significantly to the market, reflecting the broad range of health conditions requiring pharmacological intervention in the Indian population.

By Drug Type: OTC Drugs Lead, Prescription Drugs Follow

The market segmentation by drug type includes Prescription Drugs and OTC (Over-the-Counter) Drugs. The OTC drugs category generated the most income. Over-the-counter medications are those that do not require a prescription to purchase and are generally considered safe to use without a doctor's supervision. They are typically used to treat mild illnesses and symptoms such as pain, fever, cold, cough, allergies, indigestion, and skin conditions. Examples include acetaminophen (paracetamol), diphenhydramine (antihistamine), and various multivitamins.

The dominance of OTC drugs in the Indian market reflects several factors. First, the growing awareness of self-care and preventive health among Indian consumers is driving demand for OTC products. Second, the increasing availability of OTC medications through pharmacies, retail stores, and online platforms makes them easily accessible. Third, the relatively lower cost of OTC drugs compared to prescription medications makes them attractive for managing minor health issues without incurring doctor consultation fees. Fourth, the COVID-19 pandemic has further accelerated the trend towards self-medication and home management of minor illnesses, boosting OTC sales.

Prescription drugs constitute the other major segment, including medications that require a prescription from a licensed healthcare provider due to their potential for side effects, abuse, or need for professional monitoring. This category includes most chronic disease medications (for cardiovascular conditions, diabetes, respiratory diseases, etc.), antibiotics, psychotropic drugs, and many others. While OTC drugs lead in terms of volume, prescription drugs account for a significant share of market value due to their higher per-unit cost, particularly for branded generics and patented products.

The report notes that the Indian pharmaceutical industry has a long history of creating and exporting top-quality goods at competitive prices to customers all over the world. Pharmaceutical firms based in India provide products in several categories, including OTC medications, vaccines, APIs, contract research and manufacture, biosimilars, and biologics. This diversity of products across both OTC and prescription categories positions the industry to serve a wide range of healthcare needs both within India and globally.